Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer.

Mendenhall NP, Hoppe BS, Nichols RC, Mendenhall WM, Morris CG, Li Z, Su Z, Williams CR, Costa J, Henderson RH.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):596-602. doi: 10.1016/j.ijrobp.2013.11.007.

PMID:
24521677
[PubMed - indexed for MEDLINE]
2.

Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.

Mendenhall NP, Li Z, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols RC, Morris CG, Williams CR, Costa J, Henderson R.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):213-21. doi: 10.1016/j.ijrobp.2010.09.024. Epub 2010 Nov 17.

PMID:
21093164
[PubMed - indexed for MEDLINE]
3.

Urinary functional outcomes and toxicity five years after proton therapy for low- and intermediate-risk prostate cancer: results of two prospective trials.

Henderson RH, Hoppe BS, Marcus RB Jr, Mendenhall WM, Nichols RC, Li Z, Su Z, Morris CG, Williams CR, Costa J, Mendenhall NP.

Acta Oncol. 2013 Apr;52(3):463-9. doi: 10.3109/0284186X.2013.764467.

PMID:
23477359
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan.

Takeda K, Takai Y, Narazaki K, Mitsuya M, Umezawa R, Kadoya N, Fujita Y, Sugawara T, Kubozono M, Shimizu E, Abe K, Shirata Y, Ishikawa Y, Yamamoto T, Kozumi M, Dobashi S, Matsushita H, Chida K, Ishidoya S, Arai Y, Jingu K, Yamada S.

Radiat Oncol. 2012 Jul 6;7:105. doi: 10.1186/1748-717X-7-105.

PMID:
22770471
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.

Patel N, Faria S, Cury F, David M, Duclos M, Shenouda G, Ruo R, Souhami L.

Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):534-9. doi: 10.1016/j.ijrobp.2013.02.010. Epub 2013 Apr 15.

PMID:
23597418
[PubMed - indexed for MEDLINE]
6.

Hypofractionated passively scattered proton radiotherapy for low- and intermediate-risk prostate cancer is not associated with post-treatment testosterone suppression.

Kil WJ, Nichols RC Jr, Hoppe BS, Morris CG, Marcus RB Jr, Mendenhall W, Mendenhall NP, Li Z, Costa JA, Williams CR, Henderson RH.

Acta Oncol. 2013 Apr;52(3):492-7. doi: 10.3109/0284186X.2013.767983.

PMID:
23477360
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.

Wong WW, Schild SE, Vora SA, Ezzell GA, Nguyen BD, Ram PC, Roarke MC.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e423-9. doi: 10.1016/j.ijrobp.2011.01.048. Epub 2011 Apr 7.

PMID:
21477947
[PubMed - indexed for MEDLINE]
8.

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer.

Zelefsky MJ, Hollister T, Raben A, Matthews S, Wallner KE.

Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1261-6.

PMID:
10889379
[PubMed - indexed for MEDLINE]
9.

High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a Phase II trial.

Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, See A, Duchesne GM.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1889-96. doi: 10.1016/j.ijrobp.2010.09.006. Epub 2011 May 6.

PMID:
21550182
[PubMed - indexed for MEDLINE]
10.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

PMID:
21163590
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A phase II study of hypofractionated proton therapy for prostate cancer.

Kim YJ, Cho KH, Pyo HR, Lee KH, Moon SH, Kim TH, Shin KH, Kim JY, Lee SB, Nam BH.

Acta Oncol. 2013 Apr;52(3):477-85. doi: 10.3109/0284186X.2013.764011. Epub 2013 Feb 11.

PMID:
23398594
[PubMed - indexed for MEDLINE]
12.

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.

Chen LN, Suy S, Uhm S, Oermann EK, Ju AW, Chen V, Hanscom HN, Laing S, Kim JS, Lei S, Batipps GP, Kowalczyk K, Bandi G, Pahira J, McGeagh KG, Collins BT, Krishnan P, Dawson NA, Taylor KL, Dritschilo A, Lynch JH, Collins SP.

Radiat Oncol. 2013 Mar 13;8:58. doi: 10.1186/1748-717X-8-58.

PMID:
23497695
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.

Quon H, Cheung PC, Loblaw DA, Morton G, Pang G, Szumacher E, Danjoux C, Choo R, Thomas G, Kiss A, Mamedov A, Deabreu A.

Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):898-905. doi: 10.1016/j.ijrobp.2010.11.003. Epub 2011 Jan 14.

PMID:
21237581
[PubMed - indexed for MEDLINE]
14.

Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.

Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):811-7. doi: 10.1016/j.ijrobp.2009.05.054. Epub 2009 Oct 14.

PMID:
19836166
[PubMed - indexed for MEDLINE]
15.

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

Zelefsky MJ, Kollmeier M, Cox B, Fidaleo A, Sperling D, Pei X, Carver B, Coleman J, Lovelock M, Hunt M.

Int J Radiat Oncol Biol Phys. 2012 Sep 1;84(1):125-9. doi: 10.1016/j.ijrobp.2011.11.047. Epub 2012 Feb 11.

PMID:
22330997
[PubMed - indexed for MEDLINE]
16.

Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.

Jereczek-Fossa BA, Santoro L, Zerini D, Fodor C, Vischioni B, Dispinzieri M, Bossi-Zanetti I, Gherardi F, Bonora M, Caputo M, Vavassori A, Cambria R, Garibaldi C, Cattani F, Matei DV, Musi G, De Cobelli O, Orecchia R.

J Urol. 2013 Jun;189(6):2099-103. doi: 10.1016/j.juro.2013.01.005. Epub 2013 Jan 9.

PMID:
23313200
[PubMed - indexed for MEDLINE]
17.

Hypofractionated intensity-modulated simultaneous integrated boost and image-guided radiotherapy in the treatment of high-risk prostate cancer patients: a preliminary report on acute toxicity.

Valeriani M, Carnevale A, Osti MF, Minniti G, De Sanctis V, Agolli L, Bracci S, Enrici RM.

Tumori. 2013 Jul-Aug;99(4):474-9. doi: 10.1700/1361.15097.

PMID:
24326835
[PubMed - indexed for MEDLINE]
18.

A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.

Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.

J Urol. 2005 Sep;174(3):882-7.

PMID:
16093980
[PubMed - indexed for MEDLINE]
19.

Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer.

Gómez-Iturriaga Piña A, Crook J, Borg J, Lockwood G, Fleshner N.

Urology. 2010 Jun;75(6):1412-6. doi: 10.1016/j.urology.2009.04.101. Epub 2009 Dec 29.

PMID:
20035986
[PubMed - indexed for MEDLINE]
20.

Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.

Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA.

Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):343-52.

PMID:
10802358
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk